105 related articles for article (PubMed ID: 7933456)
1. Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
J Pak Med Assoc; 1994 Jul; 44(7):166-9. PubMed ID: 7933456
[TBL] [Abstract][Full Text] [Related]
2. Biochemical changes during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Ahaneku JE; Taylor GO; Walker O; Agbedana EO; Sowunmi A; Salako LA
J Pak Med Assoc; 1996 Apr; 46(4):71-3. PubMed ID: 8991356
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure and blood glucose levels during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Ahaneku JE
Kobe J Med Sci; 1996 Feb; 42(1):19-29. PubMed ID: 8984227
[TBL] [Abstract][Full Text] [Related]
4. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese patients.
Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
Pharmacol Res; 2000 Jan; 41(1):75-9. PubMed ID: 10600272
[TBL] [Abstract][Full Text] [Related]
5. Effects of moduretic on plasma lipid and lipoprotein levels in hypertensive African patients.
Ahaneku JE; Taylor GO; Agbedana OE; Walker O; Salako LA
Tokai J Exp Clin Med; 1993 Dec; 18(3-6):155-60. PubMed ID: 7701530
[TBL] [Abstract][Full Text] [Related]
6. Influence of baseline values on lipids and lipoprotein changes during amlodipine treatment of hypertension.
Ahaneku JE
Pharmacol Res; 1998 Sep; 38(3):179-82. PubMed ID: 9782067
[TBL] [Abstract][Full Text] [Related]
7. Influence of baseline values. II: Variations in plasma lipoprotein fractions during doxazosin treatment for hypertension.
Ahaneku JE; Taylor GO; Agbedana EO
Int J Clin Pharmacol Res; 1998; 18(4):165-70. PubMed ID: 10052026
[TBL] [Abstract][Full Text] [Related]
8. The effects of doxazosin on plasma lipid and lipoprotein levels in hypertensive patients.
Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
Pharmacol Res; 1994; 30(3):263-72. PubMed ID: 7862620
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.
Grimm RH; Flack JM; Grandits GA; Elmer PJ; Neaton JD; Cutler JA; Lewis C; McDonald R; Schoenberger J; Stamler J
JAMA; 1996 May 22-29; 275(20):1549-56. PubMed ID: 8622245
[TBL] [Abstract][Full Text] [Related]
10. Effects of doxazosin and hydrochlorothiazide on lipid levels in Korean patients with essential hypertension.
Jones DW; Sands CD
J Cardiovasc Pharmacol; 1993 Sep; 22(3):431-7. PubMed ID: 7504134
[TBL] [Abstract][Full Text] [Related]
11. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
Hirano T; Yoshino G; Kashiwazaki K; Adachi M
Am J Hypertens; 2001 Sep; 14(9 Pt 1):908-13. PubMed ID: 11587157
[TBL] [Abstract][Full Text] [Related]
12. Relationship between body mass index (BMI) and changes in plasma total and HDL-cholesterol levels during treatment of hypertension in African patients.
Ahaneku JE; Agbedana OE; Taylor OG
Acta Med Okayama; 1995 Oct; 49(5):267-70. PubMed ID: 8585398
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
[TBL] [Abstract][Full Text] [Related]
14. Effect of antihypertensive therapy on serum lipids in newly diagnosed essential hypertensive men.
Nandeesha H; Pavithran P; Madanmohan T
Angiology; 2009; 60(2):217-20. PubMed ID: 18445617
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
16. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.
Rabkin SW; Huff MW; Newman C; Sim D; Carruthers SG
Hypertension; 1994 Aug; 24(2):241-8. PubMed ID: 8039850
[TBL] [Abstract][Full Text] [Related]
17. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance.
Shionoiri H; Ashino K; Yamanaka K; Shindo K; Hiroto S; Arita T
Clin Ther; 1997; 19(3):527-36. PubMed ID: 9220217
[TBL] [Abstract][Full Text] [Related]
18. Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension.
Lacourcière Y; Gagné C
J Hum Hypertens; 1993 Apr; 7(2):149-52. PubMed ID: 8510087
[TBL] [Abstract][Full Text] [Related]
19. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
Lehtonen A; Himanen P; Saraste M; Niittymäki K; Marniemi J
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):77S-81S. PubMed ID: 2939871
[TBL] [Abstract][Full Text] [Related]
20. Lipid profile in 100 men with moderate hypertension treated for 1 year with atenolol or hydrochlorothiazide plus amiloride: a double-blind, randomized study.
Otterstad JE; Froeland G; Soeyland AK; Illingworth JM
Scand J Clin Lab Invest; 1992 Apr; 52(2):83-93. PubMed ID: 1589701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
